

GlaxoSmithKline Artwork Information Panel	RSC A/W Version: 1
Item Number: 1000000116742	
Manufacturing Site: GSK-ESP-Aranda-ESARA	
Market or Pack Owner: Gulf and Near East-GNE	
Market Trade Name: Votrient	
No. of Colours: 1 (does NOT include Varnish, if applicable)	
List Colours: (include sample in fields provided below; e.g. spot / spot-CMYK equivalent)	
K	
Technical Reference No(s).: 02-01-XX-273-15 (do NOT include the technical reference doc(s) version no(s))	
Artwork copyright is the property of the GlaxoSmithKline Group of Companies. All suppliers providing a service to GSK for printed components of any description must ensure that they have a licence for all fonts / software used in conjunction with GSK artwork. The distribution and use of fonts / software without a licence constitutes an intellectual property infringement. GSK will not accept any liability for the breach of third party intellectual property rights by printed component suppliers. The GSK certification / audit process requires suppliers to declare that they do not use unlicensed fonts / software and may require the supplier to produce evidence of such licence to GSK.	
ATTENTION • ATTENTION	
To Ensure Accurate PDF Viewing and Printing: FOR SCREEN VIEWING: Use Adobe Acrobat 5 Professional or Adobe Acrobat Reader, Standard or Professional (higher than 5). Overprint Preview must be activated for accurate on screen viewing. FOR PRINTING: Use only Acrobat Professional version 5 or higher. "Apply Overprint Preview" or "Simulate Overprinting" must be activated in the print settings for printing accurate hard copies.	

180 mm Measuring Bar
If a status identification banner DOES NOT appear on this document, THEN this document has NOT been printed from the Global Pack Management System.

PHARMA CODE Nº 0306



FRONT PAGE

TYPE SIZE: 9/9.8
HORIZONTAL SCALE: 90%

IMPORTANT

GSK Market is responsible for this product, its design and content. Ensure the artwork is thoroughly checked, all the text proof-read and approved. RSC GSK is responsible for site technical requirements and pre-press suitability.

GSK Market is responsible to advise RSC in case changes required impact the followings:
Formulation
Tablet embossing
Storage conditions
Shelf Life

Page 1 of 2

Votrient™

Votrient™ 200 mg film-coated tablets
Votrient™ 400 mg film-coated tablets

Pazopanib

Qualitative and Quantitative Composition

Votrient™ 200 mg: Each film-coated tablet contains 200 mg pazopanib (as hydrochloride).
Votrient™ 400 mg: Each film-coated tablet contains 400 mg pazopanib (as hydrochloride).
See (List of excipients).

Pharmaceutical form

Votrient™ 200 mg: Capsule-shaped, pink, film-coated tablet with GS JT debossed on one side.
Votrient™ 400 mg: Capsule-shaped, white, film-coated tablet with GS ULH debossed on one side.

Therapeutic indications

Renal cell carcinoma (RCC)

Votrient is indicated in adults for the first line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytotoxic therapy for advanced disease.

Soft tissue sarcoma (STS)

Votrient is indicated for the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy. Efficacy and safety has only been established in certain STS histological tumour subtypes.

Posology and method of administration

Votrient treatment should only be initiated by a physician experienced in the administration of anti-cancer agents.

Posology

Adults

The recommended dose of pazopanib for the treatment of RCC or STS is 800 mg once daily.

Dose modifications

Dose modification should be in 200 mg increments in a stepwise fashion based on individual tolerability in order to manage adverse reactions. The dose of pazopanib should not exceed 800 mg.

Paediatric population

Pazopanib should not be used in children younger than 2 years of age because of safety concerns on organ growth and maturation. The safety and efficacy of pazopanib in children aged 2 to 18 years of age have not yet been established. No data are available.

Elderly

There are limited data of the use of pazopanib in patients aged 65 years and older. In the RCC studies of pazopanib, overall no clinically significant differences in safety of pazopanib were observed between subjects aged at least 65 years and younger subjects. Clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Renal impairment

Renal impairment is unlikely to have a clinically relevant effect on pazopanib pharmacokinetics given the low renal excretion of pazopanib and metabolites. Therefore, no dose adjustment is required in patients with creatinine clearance above 30 ml/min. Caution is advised in patients with creatinine clearance below 30 ml/min as there is no experience of pazopanib in this patient population.

Hepatic impairment

Dosing recommendations in hepatically impaired patients are based on pharmacokinetic studies of pazopanib in patients with varying degrees of hepatic dysfunction. Administration of pazopanib to patients with mild or moderate hepatic impairment should be undertaken with caution and close monitoring of tolerability. 800 mg pazopanib once daily is the recommended dose in patients with mild abnormalities in serum liver tests (defined as either normal bilirubin and any degree of alanine aminotransferase (ALT) elevation or as an elevation of bilirubin (> 35 % direct) up to 1.5 x upper limit of normal (ULN) regardless of the ALT value). A reduced pazopanib dose of 200 mg once daily is recommended in patients with moderate hepatic impairment (defined as an elevation of bilirubin > 1.5 to 3 x ULN regardless of the ALT values).

Method of administration

Pazopanib is not recommended in patients with severe hepatic impairment (defined as total bilirubin > 3 x ULN regardless of any level of ALT).

Contraindications

Hypersensitivity to the active substance or to any of the excipients.

Warnings and Precautions

Hepatic Effects: Cases of hepatic failure (including fatalities) have been reported during use of pazopanib. In clinical trials with pazopanib, increase in serum transaminases (ALT, AST) and bilirubin were observed (see Adverse Reactions). In the majority of the cases, isolated increases in ALT and AST have been reported, without concomitant elevations of alkaline phosphatase or bilirubin. The vast majority (over 90 %) of all transaminase elevations of any grade occurred in the first 18 weeks. Grades are based on the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3 (NCI CTCAE).

Monitor serum liver tests before initiation of treatment with pazopanib, and at weeks 3, 5, 7 and 9. Thereafter monitor at Month 3 and at Month 4, and as clinically indicated. Periodic monitoring should then continue after Month 4.

The following guidelines are provided for patients with baseline values of total bilirubin \leq 1.5 X ULN and AST and ALT \leq 2 X ULN.

- Patients with isolated ALT elevations between 3 X ULN and 8 X ULN may be continued on pazopanib with weekly monitoring of liver function until ALT return to Grade 1 (NCI CTCAE) or baseline.
- Patients with ALT of > 8 X ULN should have pazopanib interrupted until they return to Grade 1 (NCI CTCAE) or baseline. If the potential benefit for reinitiating pazopanib treatment is considered to outweigh the risk for hepatotoxicity, then reintroduce pazopanib at a reduced dose of 400 mg once daily and measure serum liver tests weekly for 8 weeks (see Dosage and Administration). Following reintroduction of pazopanib, if ALT elevations > 3 X ULN recur, then pazopanib should be permanently discontinued.
- If ALT elevations > 3 X ULN occur concurrently with bilirubin elevations > 2 X ULN pazopanib should be permanently discontinued. Patients should be monitored until return to Grade 1 (NCI CTCAE) or baseline. Pazopanib is a UGT1A1 inhibitor. Mild, indirect (unconjugated) hyperbilirubinaemia may occur in patients with Gilbert's syndrome. Patients with only a mild indirect hyperbilirubinaemia, known or suspected Gilbert's syndrome, and elevation in ALT > 3 X ULN should be managed as per the recommendations outlined for isolated ALT elevations.

Concomitant use of pazopanib and simvastatin increases the risk of ALT elevations (see Interactions) and should be undertaken with caution and close monitoring.

Beyond recommending that patients with mild hepatic impairment are treated with 800 mg pazopanib once daily and reducing the initial starting dose to 200 mg per day for patients with moderate impairment, no further dose modification guidelines based on results of serum liver tests during therapy have been established for patients with pre-existing hepatic impairment.

Hypertension: In clinical studies with pazopanib, events of hypertension including hypertensive crisis have occurred. Blood pressure should be well controlled prior to initiating pazopanib. Patients should be monitored for hypertension early after starting treatment (no longer than one week after starting pazopanib) and frequently thereafter to ensure blood pressure control, and treated promptly with a combination of standard anti-hypertensive therapy and pazopanib dose reduction or interruption as clinically warranted (see Dosage and Administration, Adverse Reactions). Hypertension (systolic blood pressure \geq 150 or diastolic blood pressure \geq 100 mm Hg) occurs early in the course of pazopanib treatment (approximately 40% of cases occurred by Day 9 and approximately 90% of cases occurred in the first 18 weeks). Pazopanib should be discontinued if there is evidence of hypertensive crisis or if hypertension is severe and persists despite anti-hypertensive therapy and pazopanib dose reduction.

Reversible encephalopathy syndrome (PRES) / Reversible posterior leukoencephalopathy syndrome (RPLS): PRES/RPLS has been reported in association with pazopanib. PRES/RPLS can present with headache, hypertension, seizure, lethargy, confusion, blindness and other visual and neurological disturbances, and can be fatal. Permanently discontinue pazopanib in patients developing PRES/RPLS.

Cardiac Dysfunction: In clinical trials with pazopanib, events of cardiac dysfunction such as congestive heart failure and decreased left ventricular ejection fraction (LVEF) have occurred. Congestive heart failure was reported in 3 out of 240 subjects (1 %) in the phase III STS clinical trial. In this trial decreases in LVEF in subjects who had post-baseline measurement were detected in 11 % (16/142) in the pazopanib arm compared with 5 % (2/40) in the placebo arm. Fourteen of the 16 subjects in the pazopanib arm had concurrent hypertension which may have exacerbated cardiac dysfunction in patients at risk (e.g., those with prior anthracycline therapy) by increasing cardiac after-load.

Blood pressure should be monitored and managed promptly using a combination of anti-hypertensive therapy and dose modification of pazopanib (interruption and re-initiation at a reduced dose based on clinical judgment). Patients should be carefully monitored for clinical signs or symptoms of congestive heart failure. Baseline and periodic evaluation of LVEF is recommended in patients at risk of cardiac dysfunction.

QT Prolongation and Torsade de Pointes: In clinical studies with pazopanib, events of QT prolongation or Torsade de Pointes have occurred (see Adverse Reactions). Pazopanib should be used with caution in patients with a history of QT interval prolongation, patients taking antiarrhythmics or other medications that may potentially prolong QT interval, or those with relevant pre-existing cardiac disease. When using pazopanib, baseline and periodic monitoring of electrocardiograms and maintenance of electrolytes (calcium, magnesium, potassium) within normal range is recommended.

Arterial Thrombotic Events: In clinical studies with pazopanib, myocardial infarctions, angina, ischemic stroke and transient ischemic attack were observed (see Adverse Reactions). Fatal events have been observed. Pazopanib should be used with caution in patients who are at increased risk of thrombotic events or who have had a history of thrombotic events. Pazopanib has not been studied in patients who have had an event within the previous 6 months. A treatment decision should be made based upon the assessment of individual patient's benefit/risk.

Venous Thromboembolic Events: In clinical studies with pazopanib, venous thromboembolic events including venous thrombosis and fatal pulmonary embolus have occurred. The incidence was higher in the STS population (5 %) than in the RCC population (2 %).

Thrombotic Microangiopathy: Thrombotic microangiopathy (TMA) has been reported in clinical trials of pazopanib as monotherapy, in combination with bevacizumab, and in combination with topotecan (see Adverse Reactions). Permanently discontinue pazopanib in patients developing TMA. Reversal of effects of TMA has been observed after treatment was discontinued. Pazopanib is not indicated for use in combination with other agents.

Haemorrhagic Events: In clinical studies with pazopanib haemorrhagic events have been reported (see Adverse Reactions). Fatal haemorrhagic events have occurred. Pazopanib has not been studied in patients who had a history of haemoptysis, cerebral, or clinically significant gastrointestinal haemorrhage in the past 6 months. Pazopanib should be used with caution in patients with significant risk of haemorrhage.

Gastrointestinal Perforations and Fistula: In clinical studies with pazopanib, events of gastrointestinal (GI) perforation or fistula have occurred (see Adverse Reactions). Fatal perforation events have occurred. Pazopanib should be used with caution in patients at risk for GI perforation or fistula.

Wound Healing: No formal studies on the effect of pazopanib on wound healing have been conducted. Since Vascular Endothelial Growth Factor (VEGF) inhibitors may impair wound healing, treatment with pazopanib should be stopped at least 7 days prior to scheduled surgery. The decision to resume pazopanib after surgery should be based on clinical judgement of adequate wound healing. Pazopanib should be discontinued in patients with wound dehiscence.

Hypothyroidism: In clinical studies with pazopanib, events of hypothyroidism have occurred (see Adverse Reactions). Proactive monitoring of thyroid function tests is recommended.

Proteinuria: In clinical studies with pazopanib, proteinuria has been reported (see Adverse Reactions). Baseline and periodic urinalyses during treatment are recommended and patients should be monitored for worsening proteinuria. Pazopanib should be discontinued if the patient develops nephrotic syndrome.

Infections: Cases of serious infections (with or without neutropenia), in some cases with fatal outcome, have been reported.

Combination with other systemic anti-cancer therapies: Clinical trials of pazopanib in combination with pemetrexed (non-small cell lung cancer (NSCLC) and lapatinib (cervical cancer) were terminated early due to concerns over increased toxicity and/or mortality, and a safe and effective combination dose has not been established with these regimens. Pazopanib is not indicated for use in combination with other agents.

Juvenile animal toxicity: Because the mechanism of action of pazopanib can severely affect organ growth and maturation during early post-natal development (see Non-clinical information), pazopanib should not be given to human paediatric patients younger than 2 years of age.

Pregnancy: Pre-clinical studies in animals have shown reproductive toxicity.

If pazopanib is used during pregnancy, or if the patient becomes pregnant while receiving pazopanib, the potential hazard to the foetus should be explained to the patient. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with pazopanib (see Pregnancy and Lactation).

Interactions: Concomitant treatment with strong inhibitors of CYP3A4 or P-glycoprotein (P-gp) should be avoided due to risk of increased exposure to pazopanib (see Interactions). Selection of alternative concomitant medicinal products with no or minimal potential to inhibit CYP3A4 or P-gp should be considered.

Interactions

Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes

In vitro studies suggested that the oxidative metabolism of pazopanib in human liver microsomes is mediated primarily by CYP3A4, with minor contributions from CYP1A2 and CYP2C8. Therefore, inhibitors and inducers of CYP3A4 may alter the metabolism of pazopanib.

CYP3A4, P-gp, Breast Cancer Resistance Protein (BCRP) Inhibitors: Pazopanib is a substrate for CYP3A4, P-gp and BCRP

Concurrent administration of pazopanib (400 mg once daily) with the strong CYP3A4 and P-gp inhibitor, ketoconazole (400 mg once daily) for 5 consecutive days, resulted in a 66 % and 45 % increase in mean pazopanib AUC₍₀₋₂₄₎ and C_{max}, respectively, relative to administration of pazopanib alone (400 mg once daily for 7 days). Pazopanib C_{max} and AUC increase in a less than dose proportional fashion with increasing dose over the range of 50 mg to 2000 mg. Therefore, a dose reduction to 400 mg pazopanib once daily in the presence of strong CYP3A4 inhibitors will, in the majority of patients, result in systemic exposure similar to that observed after administration of 800 mg pazopanib once daily alone. Some patients however may have systemic pazopanib exposure greater than what has been observed after administration of 800 mg pazopanib alone.

Co-administration of pazopanib with other strong inhibitors of the CYP3A4 family (e.g., itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) may increase pazopanib concentrations. Grapefruit juice may also increase plasma concentrations of pazopanib.

Administration of 1500 mg lapatinib a substrate and weak inhibitor of CYP3A4, Pgp and BCRP with 800 mg pazopanib resulted in an approximately 50 % to 60 % increase in mean pazopanib AUC₍₀₋₂₄₎ and C_{max}, compared to administration of 800 mg pazopanib alone. Co-administration of pazopanib with a CYP3A4, Pgp, and BCRP inhibitor, such as lapatinib, will result in an increase in plasma pazopanib concentrations.

Concomitant use of pazopanib with a strong CYP3A4 inhibitor should be avoided. If no medically acceptable alternative to a strong CYP3A4 inhibitor is available, the dose of pazopanib should be reduced to 400 mg daily during concomitant administration (see Warnings and Precautions). Further dose reduction may be considered if possible drug-related adverse events are observed.

Combination with strong P-gp inhibitors should be avoided, or selection of an alternate concomitant medication with no or minimal potential to inhibit P-gp is recommended.

CYP3A4 Inducers: CYP3A4 inducers such as rifampin may decrease plasma pazopanib concentrations. Selection of an alternate concomitant medication with no or minimal enzyme induction potential is recommended.

Effects of Pazopanib on CYP Substrates

In vitro studies with human liver microsomes showed that pazopanib inhibited CYP enzymes 1A2, 3A4, 2B6, 2C8, 2C9, 2C19, and 2E1. Potential induction of human CYP3A4 was demonstrated in an *in vitro* human PXR assay. Clinical pharmacology studies, using pazopanib 800 mg once daily, have demonstrated that pazopanib does not have a clinically relevant effect on the pharmacokinetics of caffeine (CYP1A2 probe substrate), warfarin (CYP2C9 probe substrate), or omeprazole (CYP2C19 probe substrate) in cancer patients. Pazopanib resulted in an increase of approximately 30 % in the mean AUC and C_{max} of midazolam (CYP3A4 probe substrate) and increases of 33% to 64% in the ratio of dextromethorphan to dextrorphan concentrations in the urine after oral administration of dextromethorphan (CYP2D6 probe substrate). Co-administration of pazopanib 800 mg once daily and paclitaxel 80 mg/m² (CYP3A4 and CYP2C8 substrate) once weekly resulted in a mean increase of 26 % and 31 % in paclitaxel AUC and C_{max}, respectively.

Effects of Pazopanib on Other Enzymes and Transporters

In vitro studies also showed that pazopanib is a potent inhibitor of UGT1A1 and OATP1B1 with IC₅₀ of 1.2 and 0.79 μM, respectively. Pazopanib may increase concentrations of drugs primarily eliminated through UGT1A1 and OATP1B1.

Effect of concomitant use of Pazopanib and Simvastatin

Concomitant use of pazopanib and simvastatin increases the incidence of ALT elevations. Across monotherapy studies with pazopanib, ALT > 3xULN was reported in 126 / 895 (14 %) of patients who did not use statins, compared with 114/1 (27 %) of patients who had concomitant use of simvastatin (p = 0.038). If a patient receiving concomitant simvastatin develops ALT elevations, follow guidelines for pazopanib posology and discontinue simvastatin (see Warnings and Precautions). Insufficient data are available to assess the risk of concomitant administration of alternative statins and pazopanib.

Effect of Food on Pazopanib

Administration of pazopanib with a high-fat or low-fat meal results in an approximately 2-fold increase in AUC and C_{max}. Therefore, pazopanib should be administered at least 1 hour before or 2 hours after a meal (see Dosage and Administration).

Pregnancy and Lactation

Fertility

Pazopanib may impair fertility in human males and females. In female reproductive toxicity studies in rats, reduced female fertility has been observed.

Pregnancy

There are no adequate data from the use of pazopanib in pregnant women. Studies in animals have shown reproductive toxicity. The potential risk for humans is unknown. Pazopanib should not be used during pregnancy unless the clinical condition of the woman requires treatment with pazopanib. If pazopanib is used during pregnancy, or if the patient becomes pregnant while receiving pazopanib, the potential hazard to the foetus should be explained to the patient.

Women of childbearing potential should be advised to use adequate contraception and avoid becoming pregnant while receiving treatment with pazopanib.

Lactation

The safe use of pazopanib during lactation has not been established. It is not known whether pazopanib is excreted in human milk. Breast feeding should be discontinued during treatment with pazopanib.

Ability to perform tasks that require judgment, motor or cognitive skills

There have been no studies to investigate the effect of pazopanib on driving performance or the ability to operate machinery. A detrimental effect on such activities would not be anticipated from the pharmacology of pazopanib. The clinical status of the patient and the adverse event profile of pazopanib should be borne in mind when considering the patient's ability to perform task that require judgment, motor and cognitive skills.

Adverse Reactions

The safety and efficacy of pazopanib in renal cell carcinoma (RCC) were evaluated in a randomized, double-blind, placebo-controlled multi-centre study. Patients with locally advanced and/or metastatic RCC were randomized to receive pazopanib 800 mg once daily (N=290) or placebo (N=145). The median duration of treatment was 7.4 months for the pazopanib arm and 3.8 months for the placebo arm.

The safety and efficacy of pazopanib in soft tissue sarcoma (STS) were evaluated in a randomized, double-blind, placebo-controlled multi-centre study. Patients (N = 369) with advanced STS who had received prior anthracycline treatment, or were unsuited for such therapy, were randomized to receive pazopanib 800 mg once daily (N = 246) or placebo (N = 123). The median duration of treatment was 4.5 months for the pazopanib arm and 1.9 months for the placebo arm.

Adverse reactions are listed below by MedDRA body system organ class.

The following convention has been utilised for the classification of frequency:

Very common \geq 1 in 10

Common \geq 1 in 100 and < 1 in 10

Uncommon \geq 1 in 1,000 and < 1 in 100

Categories have been assigned based on absolute frequencies in the clinical trial data.

Table 1 Adverse reactions, by organ class and frequency, reported in RCC (VEG105192) and STS (VEG110727) studies

	Frequency classification	
	RCC VEG105192 n=290	STS VEG110727 n=240
Blood and lymphatic system disorders		
Neutropenia	Common	♦
Thrombocytopenia	Common	♦
Endocrine disorders		
Hypothyroidism*	Common	Common
Metabolic and nutrition disorders		
Anorexia	Very common	Very common
Weight decreased	Common	Very common
Nervous system disorders		
Dizziness	♦	Very common
Dysgeusia	Common	Very common
Headache	Very common	Very common
Ischaemic stroke*	Uncommon	Uncommon
Transient ischaemic attack*	Common	♦
Cardiac disorders		
Cardiac dysfunction (such as a decrease in ejection fraction and congestive heart failure)*	Uncommon	Common
Bradycardia (asymptomatic)†	Very common	Very common
Myocardial infarction*	Uncommon	Common
Myocardial ischaemia	Common	♦
QT prolongation*	Common	Common
Torsade de Pointes*	Uncommon	♦
Vascular disorders		
Cerebral haemorrhage*	Uncommon	Uncommon
Epistaxis	Common	Common
Gastrointestinal haemorrhage*	Uncommon	Uncommon
Haematuria	Common	Uncommon
Hypertension*	Very common	Very common
Pulmonary haemorrhage*	Uncommon	Common
Venous thromboembolic events*	Uncommon	Common
Respiratory, thoracic and mediastinal disorders		
Cough	♦	Very common
Dysphonia	Common	Common
Dyspnoea	♦	Very common
Pneumothorax	♦	Common
Gastrointestinal disorders		
Abdominal pain	Very common	Very common
Diarrhoea	Very common	Very common
Dyspepsia	Common	Common
Gastrointestinal perforation*	Uncommon	♦
Gastrointestinal fistula*	Uncommon	Uncommon
Lipase elevations	Common	♦
Nausea	Very common	Very common
Stomatitis	♦	Very common
Vomiting	Very common	Very common
Hepatobiliary disorders		
Alanine aminotransferase increased	Very common	Common
Aspartate aminotransferase increased	Very common	Common
Hepatic function abnormal	Common	♦
Hyperbilirubinaemia	Common	Uncommon
Skin and subcutaneous tissue disorders		
Alopecia	Common	Very common
Dry skin	♦	Common
Exfoliative reaction	♦	Very common
Hair depigmentation	Very common	Very common
Nail disorder	♦	Common
Palmar-plantar erythrodysesthesia syndrome	Common	Very common
Rash	Common	Uncommon
Skin depigmentation	Common	Very common
Musculoskeletal and connective tissue disorders		
Musculoskeletal pain	♦	Very common
Myalgia	♦	Very common
Renal and urinary disorders		
Proteinuria*	Common	Uncommon
General disorders and administration site disorders		
Asthenia	Very common	Uncommon
Chest pain*	Common	Very common
Chills	♦	Common
Fatigue	Very common	

GlaxoSmithKline Artwork Information Panel	RSC A/W Version: 1
Item Number: 1000000116742	
Manufacturing Site: GSK-ESP-Aranda-ESARA	
Market or Pack Owner: Gulf and Near East-GNE	
Market Trade Name: Votrient	
No. of Colours: 1 (does NOT include Varnish, if applicable)	
List Colours: (include sample in fields provided below: e.g. spot / spot-CMYK equivalent)	
K	
Technical Reference No(s): 02-01-XX-273-15 (do NOT include the technical reference doc(s) version no(s))	
Artwork copyright is the property of the GlaxoSmithKline Group of Companies All suppliers providing a service to GSK for printed components of any description must ensure that they have a licence for all fonts / software used in conjunction with GSK artwork. The distribution and use of fonts / software without a licence constitutes an intellectual property infringement. GSK will not accept any liability for the breach of third party intellectual property rights by printed component suppliers. The GSK certification / audit process requires suppliers to declare that they do not use unlicensed fonts / software and may require the supplier to produce evidence of such licence to GSK.	
ATTENTION • ATTENTION	
To Ensure Accurate PDF Viewing and Printing: FOR SCREEN VIEWING: Use Adobe Acrobat 5. Professional or Adobe Acrobat Reader, Standard or Professional (higher than 5). Overprint Preview must be activated for accurate on screen viewing. FOR PRINTING: Use only Acrobat Professional version 5 or higher. "Apply Overprint Preview" or "Simulate Overprinting" must be activated in the print settings for printing accurate hard copies.	

180 mm Measuring Bar
If a status identification banner DOES NOT appear on this document, THEN this document has NOT been printed from the Global Print Management System.

BACK PAGE

TYPE SIZE: 9/9.8
HORIZONTAL SCALE: 90%

IMPORTANT

GSK Market is responsible for this product, its design and content.
Ensure the artwork is thoroughly checked, all the text proof-read and approved.
RSC GSK is responsible for site technical requirements and pre-press suitability.
GSK Market is responsible to advise RSC in case changes required impact the followings:
Formulation
Tablet embossing
Storage conditions
Shelf Life

Table 2 presents laboratory abnormalities occurring in ≥ 15 % of patients who received pazopanib in the pivotal RCC studies. Grades are based on the NCI CTCAE

Table 2 Selected Laboratory Abnormalities in ≥ 15 % of Patients who Received Pazopanib and More Commonly than Placebo Arm (VEG105192)

Parameters	Pazopanib (N = 290)			Placebo (N = 145)		
	All Grades %	Grade 3 %	Grade 4 %	All Grades %	Grade 3 %	Grade 4 %
Haematological						
Leukopenia	37	0	0	6	0	0
Neutropenia	34	1	<1	6	0	0
Thrombocytopenia	32	<1	<1	5	0	<1
Lymphocytopenia	31	4	<1	24	1	0
Chemistry						
ALT increased	53	10	2	22	1	0
AST increased	53	7	<1	19	<1	0
Glucose increased	41	<1	0	33	1	0
Total Bilirubin increased	36	3	<1	10	1	<1
Phosphorus decreased	34	4	0	11	0	0
Calcium decreased	33	1	1	26	1	<1
Sodium decreased	31	4	1	24	4	1
Potassium increased	27	4	<1	23	5	0
Creatinine increased	26	0	<1	25	<1	0
Magnesium decreased	26	<1	1	14	0	0
Glucose decreased	17	0	<1	3	0	0

Table3 presents laboratory abnormalities occurring in ≥ 15 % of patients who received pazopanib in the pivotal STS study. Grades are based on the NCI CTCAE

Table 3 Selected Laboratory Abnormalities in ≥ 15 % of Patients who Received Pazopanib and More Common than Placebo Arm (VEG110727)

Parameters	Pazopanib (N = 240)			Placebo (N = 123)		
	All Grades %	Grade 3 %	Grade 4 %	All Grades %	Grade 3 %	Grade 4 %
Haematological						
Leukopenia	44	1	0	15	0	0
Neutropenia	33	4	0	7	0	0
Thrombocytopenia	36	3	<1	6	0	0
Lymphocytopenia	43	10	0	36	9	2
Anaemia	27	5	2	23	<1	<1
Chemistry						
ALP increased	32	3	0	23	<1	0
ALT increased	46	8	2	18	2	<1
AST increased	51	5	3	22	2	0
Albumin increased	34	<1	0	21	0	0
Glucose increased	45	<1	0	35	2	0
Total Bilirubin increased	29	1	0	7	2	0
Sodium decreased	31	4	0	20	3	0
Potassium increased	16	1	0	11	0	0

Post Marketing Data
The following adverse reactions have been identified during post-approval use of pazopanib. This includes spontaneous case reports as well as serious adverse events from ongoing studies, clinical pharmacology studies and exploratory studies in unapproved indications.

Infections and infestations

Uncommon Infections (with or without neutropenia)

Blood and lymphatic system disorders

Rare Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome)

Nervous system disorders

Rare Posterior reversible encephalopathy syndrome

Gastrointestinal disorders

Uncommon Pancreatitis

Hepatobiliary disorders

Common Gamma-glutamyl transpeptidase increased

Musculoskeletal and connective tissue disorders

Very common Arthralgia

Overdosage

Pazopanib doses up to 2,000 mg have been evaluated in clinical trials. Grade 3 fatigue (dose limiting toxicity) and Grade 3 hypertension were each observed in 1 of 3 patients dosed at 2,000 mg and 1,000 mg daily, respectively.

Symptoms and signs

There is currently limited experience with overdosage in pazopanib.

Treatment

Further management should be as clinically indicated or as recommended by the national poisons centre, where available. Haemodialysis is not expected to enhance the elimination of pazopanib because pazopanib is not significantly renally excreted and is highly bound to plasma proteins.

Clinical Pharmacology

Pharmacodynamics

ATC Code

Pharmacotherapeutic group: Antineoplastic agents – Protein kinase inhibitor, ATC Code: L01XE11.

Mechanism of Action

Pazopanib is an orally administered, potent multi-target tyrosine kinase inhibitor (TKI) of Vascular Endothelial Growth Factor Receptors (VEGFR)-1, -2, and -3, platelet-derived growth factor (PDGFR)-α and -β, and stem cell factor receptor (c-KIT), with

IC_{50} values of 10, 30, 47, 71, 84 and 74 nM, respectively. In preclinical experiments, pazopanib dose-dependently inhibited

ligand-induced auto-phosphorylation of VEGFR-2, c-KIT and PDGFR-β receptors in cells. *In vivo*, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in various animal models, and the growth of multiple human tumour xenografts in mice.

Pharmacokinetics

Absorption

Pazopanib is absorbed orally with median time to achieve peak concentrations of 2.0 to 4.0 hours after the dose. Daily dosing results in 1.23- to 4-fold increase in AUC. There was no consistent increase in AUC and C_{max} when the pazopanib dose increased above 800 mg.

Systemic exposure to pazopanib is increased when administered with food. Administration of pazopanib with a high-fat or low-fat meal results in an approximately 2-fold increase in AUC and C_{max} . Therefore, pazopanib should be administered at least 1 hour before or 2 hours after a meal.

Administration of a single pazopanib 400 mg crushed tablet increased $AUC_{(0-24)}$ by 46% and C_{max} by approximately 2 fold and decreased t_{max} by approximately 1.5 hours compared to administration of the whole tablet. These results indicate that the bioavailability and the rate of pazopanib oral absorption are increased after administration of the crushed tablet relative to administration of the whole tablet. Therefore, due to this potential for increased exposure, tablets should not be crushed.

Distribution

Binding of pazopanib to human plasma protein *in vivo* was greater than 99 % with no concentration dependence over the range of 10-100 µg/ml. *In vitro* studies suggest that pazopanib is a substrate for P-glycoprotein (Pgp) and breast cancer resistant protein (BCRP).

Metabolism

Results from *in vitro* studies demonstrated that the metabolism of pazopanib is mediated primarily by CYP3A4, with minor contributions from CYP1A2 and CYP2C8.

Elimination

Pazopanib is eliminated slowly with mean half-life of 30.9 hours after administration of the recommended dose of 800 mg. Elimination is primarily via faeces with renal elimination accounting for < 4 % of the administered dose.

Special Populations

Renal Impairment

In a population pharmacokinetic analysis using 408 subjects with various cancers, creatinine clearance (30-150 ml/min) did not influence clearance of pazopanib. Renal impairment is not expected to influence pazopanib exposure, and dose adjustment is not necessary in patients with creatinine clearance ≥ 30 ml/min.

Hepatic Impairment

The median steady-state pazopanib $C_{min,24}$ and $AUC_{(0-24)}$ in patients with mild hepatic impairment (defined as either normal bilirubin and any degree of ALT elevations or as an elevation of bilirubin up to 1.5 x ULN regardless of the ALT value) after a once daily dose of 800 mg/day (30.9 µg/ml, range 12.5-47.3 and 841.8 µg.hr/ml, range 600.4-1078) are similar to the median in patients with no hepatic impairment (49.4 µg/ml, range 17.1-85.7 and 888.2 µg.hr/ml, range 345.5-1482) (see *Dosage and Administration*).

The maximally tolerated pazopanib dose (MTD) in patients with moderate hepatic impairment (defined as an elevation of bilirubin > 1.5 x to 3 x ULN regardless of the ALT values) was 200 mg once daily. The median steady-state values of C_{max} (22.4 µg/ml, range 6.4-32.9) and $AUC_{(0-24)}$ (350.0 µg.hr/ml, range 131.8-487.7) after administration of 200 mg pazopanib once daily in subjects with moderate hepatic impairment were approximately 45 % and 39 %, respectively, that of the corresponding median values after administration of 800 mg once daily in subjects with normal hepatic function (see *Dosage and Administration*).

There are insufficient data in patients with severe hepatic impairment (total bilirubin > 3 x ULN regardless of any level of ALT); therefore, use of pazopanib is not recommended in these patients.

Clinical Studies

Renal Cell Carcinoma (RCC)

The safety and efficacy of pazopanib in renal cell carcinoma (RCC) were evaluated in a randomized, double-blind, placebo-controlled multi-centre study. Patients (N= 435) with locally advanced and/or metastatic RCC were randomized to receive pazopanib 800 mg once daily or placebo.

The primary objective of the study was to evaluate and compare the two treatment arms for progression-free survival (PFS) and the principle secondary endpoint is overall survival (OS). The other objectives were to evaluate the overall response rate and duration of response.

From the total of 435 patients in this study, 233 patients were treatment naïve and 202 were second line patients who received one prior IL-2 or INF-α-based therapy. The performance status (ECOG) was similar between the pazopanib and placebo groups

(ECOG 0: 42 % vs. 41 %, ECOG 1: 58 % vs. 59 %). All patients had clear cell histology or predominantly clear cell histology. Approximately half of all patients had 3 or more organs involved in their disease and most patients had the lung (74 %), and/or lymph nodes (54 %) as a metastatic location for disease at baseline.

A similar proportion of patients in each arm were treatment-naïve and cytokine-pre-treated (53 % and 47 % in pazopanib arm, 54 % and 46 % in placebo arm). In the cytokine-pre-treated subgroup, the majority (75 %) had received interferon based treatment.

Similar proportions of patients in each arm had prior nephrectomy (89 % and 88 % in the pazopanib and placebo arms, respectively) and/or prior radiotherapy (22 % and 15 % in the pazopanib and placebo arms, respectively).

The primary analysis of the primary endpoint PFS is based on disease assessment by independent radiological review in the entire study population (first line and second line).

Table 4. Overall Efficacy Results by Independent Review Committee (IRC)

Endpoints/ Study population	Pazopanib		Placebo (months)	HR (95% CI)	P value (one-sided)
	N	Median			
PFS					
Overall	N=290	9.2	N=145	4.2	0.46 (0.34, 0.62)
Treatment-naïve	N=155	11.1	N=78	2.8	0.40 (0.27, 0.60)
Cytokine pre-treated	N=135	7.4	N=67	4.2	0.54 (0.35, 0.84)
Response rate	% (95% CI)				
Overall	N=290	30 (25.1, 35.6)	N=145	3 (0.5, 6.4)	<0.001

CI: confidence interval; HR: hazard ratio; ITT: Intent-to-treat; PFS: progression free survival.

For patients who responded to treatment, the median duration of response was 58.7 weeks as per independent review. The median overall survival (OS) data at the protocol specified final survival analysis were 22.9 months and 20.5 months

[HR = 0.91 (95 % CI: 0.71, 1.16); p = 0.224] for patients randomized to the pazopanib and placebo arms, respectively. The OS results are subject to potential bias as 54 % of patients in the placebo arm also received pazopanib in the extension part of this study following disease progression.

Sixty-six percent of placebo patients received post-study therapy compared to 30 % of pazopanib patients.

In the pivotal study, the QoL assessments were based on blinded self-reported global scores from two protocol-specified questionnaires, EORTC QLQ-C30 and EuroQoL EQ-5D. Analysis was based on patients who continued on therapy in both arms, prior to progression. The assessments showed no difference between treatment with pazopanib or placebo (p > 0.05), indicating no negative impact of pazopanib on global quality of life.

In a Phase 2 study of 225 patients with locally recurrent or metastatic clear cell renal cell carcinoma, objective response rate was 35 % and median duration of response was 68 weeks, as per independent review.

Soft tissue sarcoma (STS)

The safety and efficacy of pazopanib in STS were evaluated in a randomized, double-blind, placebo-controlled multi-centre study. Patients (N=369) with advanced STS who had received prior chemotherapy, including anthracycline treatment, or were unsuited for such therapy, were randomized to receive pazopanib 800 mg once daily or placebo.

Prior to randomization, eligible subjects were stratified by the factors of WHO performance status (WHO PS) (0 or 1) at baseline and the number of lines of prior systemic therapy for advanced disease (0 or 1 vs. 2+). In each treatment group, there were a slightly greater percentage of subjects in the 2+ lines of prior systemic therapy for advanced disease (58 % and 55 % respectively for placebo and pazopanib treatment arms) compared with 0 or 1 lines of prior systemic therapy (42 % and 45 % respectively for placebo and pazopanib treatment arms). There were slightly more subjects with a WHO PS of 1 at baseline. The median duration of follow-up of subjects (defined as date of randomization to date of last contact or death) was similar for both treatment arms (9.36 months for placebo [range 0.69 to 23.0 months] and 10.04 months for pazopanib [range 0.2 to 24.3 months]).

The primary objective of the study was to evaluate and compare the two treatment arms for progression-free survival (PFS), based on the ITT population, and the principle secondary endpoint is overall survival (OS).

The initial analysis of the primary endpoint PFS was based on disease assessment by independent radiological review in the entire ITT study population.

Table 5: Overall efficacy results in STS by independent assessment (VEG110727)

Endpoints/Study Population	Pazopanib	Placebo	HR (95% CI)	P value (one-sided)
PFS				
Overall* ITT	N = 246	N = 123		
Median (weeks)	20.0	7.0	0.35 (0.26, 0.48)	< 0.001
Response Rate (CR + PR) % (95 % CI)	4 (2.3, 7.9)	0 (0.0, 3.0)	-	-
Duration of response				
Median (weeks) (95 % CI)	38.9 (16.7, 40.0)	-	-	-
PFS				
Leiomyosarcoma	N = 109	N = 49		
Median (weeks)	20.1	8.1	0.37 (0.23, 0.60)	< 0.001
Synovial sarcoma	N = 25	N = 13		
Median (weeks)	17.9	4.1	0.43 (0.19, 0.98)	0.005
'Other' STS	N = 112	N = 61		
Median (weeks)	20.1	4.3	0.39 (0.25, 0.60)	< 0.001

HR = Hazard ratio; ITT = Intent to treat; PFS = Progression-free survival; CR = Complete Response; PR = Partial Response.

Similar to the assessments by independent radiology review, a clinically meaningful and statistically significant improvement in PFS based on investigator assessments was observed in the pazopanib arm compared with the placebo arm (HR: 0.39; 95 % CI, 0.30 to 0.52, p < 0.001).

The hazard ratio at the pre-specified interim analysis for overall survival in favour of pazopanib was not statistically significant; the median overall survival in the placebo arm was 10.4 months (95 % CI 8.7 to 12.7) and was 11.9 months (95 % CI 10.7 to 15.1) in the pazopanib arm; HR = 0.82 (97.87 % CI: 0.59 to 1.14, p = 0.156).

Non-clinical information

Carcinogenesis, Mutagenesis, Impairment of Fertility

Although definitive carcinogenicity studies with pazopanib have not been performed, mice given 1,000 mg/kg/day (approximately 1.5 times the human clinical exposure based on AUC) for 13 weeks had proliferative lesions noted in the liver including eosinophilic foci in 2 females and a single case of adenoma in another female.

Pazopanib did not cause genetic damage when tested in genotoxicity assays (Ames assay, human peripheral lymphocyte chromosome aberration assay, and rat *in vivo* micronucleus assay).

In female rats, reduced fertility including increased pre- and post-implantation loss, early resorptions, were noted at dosages ≥ 10 mg/kg/day (approximately 0.2 times the human clinical exposure based on AUC). Decreased corpora lutea were noted in monkeys given 500 mg/kg/day for up to 34 weeks, in mice given ≥ 100 mg/kg/day for 13 weeks and ovarian atrophy was noted in rats given 300 mg/kg/day for 26 weeks (approximately equal to, 0.6, 1.4 and 0.9 times the human clinical exposure based on AUC, respectively).

Pazopanib did not affect mating or fertility in male rats. However, there were reductions in sperm production rates, sperm motility, and epididymal and testicular sperm concentrations observed at ≥ 100 mg/kg/day (approximately 0.5 times the human clinical exposure based on AUC) following 15 weeks of dosing. Following 26 weeks of dosing, there were decreased testicular and epididymal weights, atrophy and degeneration of the testes with aspermia, hypospermia and cribriform change in the epididymis of male rats given doses ≥ 30 mg/kg/day (approximately 0.4 times the human clinical exposure based on AUC).

Pazopanib produced foetal teratogenic effects (including cardiovascular malformations and delayed ossification), reduced foetal body weight, and embryo lethality in rats at a dose level of ≥ 3 mg/kg/day (approximately 0.1 times the human clinical exposure based on AUC). In rabbits, maternal toxicity (body weight loss, reduced food consumption, and abortion) were observed at doses ≥ 30 mg/kg/day (approximately 0.007 times the human clinical exposure based on AUC), while foetal weight was reduced at doses ≥ 3 mg/kg/day. (see *Pregnancy and Lactation, Warnings and Precautions*).

Animal Toxicology and/or Pharmacology

In toxicology studies in rats, there were effects in a variety of tissues (bone, teeth, bone marrow, nail beds, reproductive organs, haematological tissues, kidney, adrenal glands, lymph node, pituitary, and pancreas) consistent with VEGFR inhibition and/or disruption of VEGF signalling pathways with some effects occurring at doses of 3 mg/kg/day (approximately 0.1 times the human clinical exposure based on AUC).

Hepatic effects included mild elevations of liver transaminases in rodents and bilirubin elevations in monkeys without associated histopathology at doses that produced systemic exposures approximately 0.1 and 0.6 times the human clinical exposure, respectively.

In juvenile toxicity studies, when pre-weaning rats were dosed from day 9 post partum through day 14 postpartum, pazopanib caused mortalities and abnormal organ growth/maturation in kidney, lung, liver and heart, at a dose approximately 0.1 times the clinical exposure based on AUC in adults. When post weaning rats were dosed from day 21 post partum to day 62 post partum, toxicologic findings were similar to adult rats at comparable exposures with changes in bone, trachea, teeth, adrenal, pancreas, stomach, duodenum, lymph node, male mammary gland and reproductive organs. In rats, weaning occurs at day 21 postpartum which approximately equates to a human paediatric age of 2 years.

Human pediatric patients are at increased risk for bone and teeth effects as compared to adults, as these changes, including shortened limbs, were present in juvenile rats at ≥ 10 mg/kg/day (equal to approximately 0.1-0.2 times the clinical exposure based on AUC in adults) (see *Warnings and Precautions*).

List of excipients

Tablet Core – 200 mg and 400 mg

Magnesium stearate

Microcrystalline cellulose

Povidone (K30)